EVAXION BIOTECH A/S (EVAX) Stock News
NASDAQ:EVAX - Nasdaq - US29970R2040 - ADR - Currency: USD
EVAX Latest News, Press Releases and Analysis
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
There are notable gap-ups and gap-downs in today's session.
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.
Evaxion announces pricing of $10.8 million public offering
COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing...
Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity...
In today's session, these stocks are experiencing unusual volume.
Discover the stocks with unexpected trading volume in today's session on the US markets.
Friday's after hours session: top gainers and losers
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Top movers in Friday's session
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Top movers in Friday's session
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Friday's session: gap up and gap down stocks
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Which stocks are moving before the opening bell on Friday?
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Stay updated with the stocks that are on the move in today's after-hours session.
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Evaxion announces completion of ADS ratio change
COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in...
Which stocks are moving on Tuesday?
Top movers analysis one hour before the close of the markets on 2025-01-14: top gainers and losers in today's session.
What's going on in today's session
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Tuesday's session: gap up and gap down stocks
Gapping stocks in Tuesday's session
Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing...
Evaxion announces plan to implement ADS ratio change
COPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing...
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results also...
Evaxion announces business update and third quarter 2024 financial results
Evaxion announces business update and third quarter 2024 financial results
COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing...
Evaxion to announce business update and third quarter 2024 financial results on October 31
COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing...
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets...
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine...
Evaxion significantly expands vaccine development collaboration with MSD
Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call...
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein...
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors...
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to...
EVAX Stock Earnings: Evaxion Biotech Beats EPS, Beats Revenue for Q2 2024
EVAX stock results show that Evaxion Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
EVAX Stock Earnings: Evaxion Biotech Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Evaxion Biotech (NASDAQ:EVAX) just reported results for the second quarter of 2...
Evaxion Announces Business Update and Second Quarter 2024 Financial Results
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company...
Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in...
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform...